La bourse est fermée

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
312,47-2,25 (-0,71 %)
À la clôture : 04:00PM EDT
314,98 +2,51 (+0,80 %)
Échanges après Bourse : 07:28PM EDT

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers - General
Employés à temps plein26 700

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Robert A. BradwayChairman, CEO & President6,73MS.O.1963
Mr. Peter H. GriffithExecutive VP & CFO3,07MS.O.1959
Mr. Esteban SantosExecutive Vice President of Operations3,01MS.O.1968
Dr. David M. Reese M.D.Executive VP & Chief Technology Officer3,4MS.O.1963
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations3,24MS.O.1967
Mr. Matthew C. BuschChief Accounting Officer & VP of FinanceS.O.S.O.1974
Mr. Mike ZahigianSenior VP & Chief Information OfficerS.O.S.O.S.O.
Dr. James E. Bradner M.D.Executive VP of Research and Development & Chief Scientific OfficerS.O.S.O.1972
Justin G. ClaeysVice President of Investor RelationsS.O.S.O.S.O.
Mr. Jonathan P. GrahamExecutive VP, General Counsel & Secretary2,44MS.O.1961
Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Amgen Inc. en date du 1 mai 2024 est 2. Les scores principaux sont Audit : 2; Société : 9; Droits des actionnaires : 1; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.